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Background: Drug pharmacokinetics parameters, drug interaction parameters, and pharmacogenetics data have
been unevenly collected in different databases and published extensively in the literature. Without appropriate
pharmacokinetics ontology and a well annotated pharmacokinetics corpus, it will be difficult to develop text
mining tools for pharmacokinetics data collection from the literature and pharmacokinetics data integration from
multiple databases.
Description: A comprehensive pharmacokinetics ontology was constructed. It can annotate all aspects of in vitro
pharmacokinetics experiments and in vivo pharmacokinetics studies. It covers all drug metabolism and
transportation enzymes. Using our pharmacokinetics ontology, a PK-corpus was constructed to present four classes
of pharmacokinetics abstracts: in vivo pharmacokinetics studies, in vivo pharmacogenetic studies, in vivo drug
interaction studies, and in vitro drug interaction studies. A novel hierarchical three level annotation scheme was
proposed and implemented to tag key terms, drug interaction sentences, and drug interaction pairs. The utility of
the pharmacokinetics ontology was demonstrated by annotating three pharmacokinetics studies; and the utility of
the PK-corpus was demonstrated by a drug interaction extraction text mining analysis.
Conclusions: The pharmacokinetics ontology annotates both in vitro pharmacokinetics experiments and in vivo
pharmacokinetics studies. The PK-corpus is a highly valuable resource for the text mining of pharmacokinetics
parameters and drug interactions.Background
Pharmacokinetics (PK) is a very important translational re-
search field, which studies drug absorption, disposition, me-
tabolism, excretion, and transportation (ADMET). PK
systematically investigates the physiological and biochem-
ical mechanisms of drug exposure in multiple tissue types,
cells, animals, and human subjects [1]. There are two major
molecular mechanisms of a drug’s PK: metabolism and
transportation. The drug metabolism mainly happens in
the gut and liver; while drug transportation exists in all tis-
sue types. If the PK can be interpreted as how a body does
on the drug, pharmacodynamics (PD) can be defined as* Correspondence: lali@iupui.edu
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reproduction in any medium, provided the orhow a drug does on the body. A drug’s pharmacodynamics
effect ranges widely from the molecular signals (such as its
targets or downstream biomarkers) to clinical symptoms
(such as the efficacy or side effect endpoints) [1].
Drug-drug interaction (DDI) is another important
pharmacology concept. It is defined as whether one drug’s
PK or PD response is changed due to the presence of an-
other drug. PD based drug interaction has a wide range of
interpretations (i.e. from molecular markers to clinical
endpoints). PK based drug interaction mechanism is very
well defined: metabolism enzyme based and transporter
based DDIs. Pharmacogenetic (PG) variations in a drug’s
PK and PD pathways can also affect its responses [1]. In
this paper, we will focus our discussion on the PK, PK
based DDI, and PK related PG.
Although significant efforts have been invested to inte-
grate biochemistry, genetics, and clinical information for
drugs, significant gaps exist in the area of PK. For example. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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PK and its associated DDI data; DiDB (http://www.drugin-
teractioninfo.org/) doesn’t have sufficient PG data; and
PharmGKB (http://www.pharmgkb.org/) doesn’t have suf-
ficient in vivo and in vitro PK and its associated DDI data.
As an alternative approach to collect PK from the pub-
lished literature, text mining has just started to be
explored [1-4].
From either database construction or literature min-
ing, the main challenge of PK data integration is the lack
of PK ontology. This paper developed a PK ontology
first. Then, a PK corpus was constructed. It facilitated
DDI text mining from the literature.
Construction and content
PK Ontology is composed of several components: experi-
ments, metabolism, transporter, drug, and subject
(Table 1). Our primary contribution is the ontology devel-
opment for the PK experiment, and integration of the PK
experiment ontology with other PK-related ontologies.
Experiment specifies in vitro and in vivo PK studies
and their associated PK parameters. Table 2 presents
definitions and units of the in vitro PK parameters. The
PK parameters of the single drug metabolism experi-
ment include Michaelis-Menten constant (Km), max-
imum velocity of the enzyme activity (Vmax), intrinsic
clearance (CLint), metabolic ratio, and fraction of metab-
olism by an enzyme (fmenzyme) [5]. In the transporter
experiment, the PK parameters include apparent perme-
ability (Papp), ratio of the basolateral to apical perme-
ability and apical to basolateral permeability (Re),
radioactivity, and uptake volume [6]. There are multiple
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ontologies/42067non-competitive inhibition, uncompetitive inhibition,
mechanism based inhibition, and induction [7]. IC50 is
the inhibition concentration that inhibits to 50% enzyme
activity; it is substrate dependent; and it doesn’t imply
the inhibition mechanism. Ki is the inhibition rate con-
stant for competitive inhibition, noncompetitive inhib-
ition, and uncompetitive inhibition. It represents the
inhibition concentration that inhibits to 50% enzyme ac-
tivity, and it is substrate concentration independent. Kdeg
is the degradation rate constant for the enzyme. KI is the
concentration of inhibitor associated with half maximal
Inactivation in the mechanism based inhibition; and
Kinact is the maximum degradation rate constant in the
presence of a high concentration of inhibitor in the
mechanism based inhibition. Emax is the maximum in-
duction rate, and EC50 is the concentration of inducer
that is associated with the half maximal induction
The in vitro experiment conditions are presented in
Table 3. Metabolism enzyme experiment conditions in-
clude buffer, NADPH sources, and protein sources.
In particular, protein sources include recombinant
enzymes, microsomes, hepatocytes, and etc. Sometimes,
genotype information is available for the microsome or
hepatocyte samples. Transporter experiment conditions
include bi-directional transporter, uptake/efflux, and
ATPase. Other factors of in vitro experiments include
pre-incubation time, incubation time, quantification
methods, sample size, and data analysis methods. All
these info can be found in the FDA website (http://www.
abclabs.com/Portals/0/FDAGuidance_DraftDrugInterac-
tionStudies2006.pdf ).
The in vivo PK parameters are presented in Table 4.
All of the information are summarized from two text
books [1,8]. There are several main classes of PK para-
meters. Area under the concentration curve parameters
are (AUCinf, AUCSS, AUCt, AUMC); drug clearance
parameters are (CL, CLb, CLu, CLH, CLR, CLpo, CLIV,
CLint, CL12); drug concentration parameters are (Cmax,
CSS); extraction ratio and bioavailability parameters are
(E, EH, F, FG, FH, FR, fe, fm); rate constants include elim-
ination rate constant k, absorption rate constant ka,
urinary excretion rate constant ke, Michaelis-Menten
constant Km, distribution rate constants (k12, k21), and
two rate constants in the two-compartment model (λ1,
λ2); blood flow rate (Q, QH); time parameters (tmax, t1/2);
volume distribution parameters (V, Vb, V1, V2, Vss); max-
imum rate of metabolism, Vmax; and ratios of PK para-
meters that present the extend of the drug interaction,
(AUCR, CL ratio, Cmax ratio, Css ratio, t1/2 ratio).
It is also shown in Table 4 that two types of pharmaco-
kinetics models are usually presented in the literature:
non-compartment model and one or two-compartment
models. There are multiple items need to be considered
in an in vivo PK study. The hypotheses include the effect
Table 2 In vitro PK parameters
Experiment
types




Km Michaelis-Menten constant. mg L
-1 Segel p28.




CLint Intrinsic metabolic clearance is defined as ratio of
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fmenzyme Fraction of drug systemically available that is














Radioactivity Total radioactivity in plasma and bile samples is





Uptake Volume The amount of radioactivity associated with the cells









IC50 Inhibitor concentration that inhibits to 50% of
enzyme activity.
mg L-1
Ki Inhibition rate constant for competitive inhibition,
noncompetitive inhibition, and uncompetitive
inhibition.
mg L-1 Segel p103





KI The concentration of inhibitor associated with half





Kinact The maximum degradation rate constant in the





Emax Maximum induction rate Unit free Rostami-
Hodjegan
and Tucker
EC50 The concentration of inducer that is associated with







inhibition, uncompetitive inhibition, mechanism
based inhibition, and induction.
Rostami-Hodjegan and Tucker
Note: Segel H. Irwin. Enzyme Kinetics – Behavior and analysis of rapid equilibrium and steady state enzyme systems. John Wiley & Sons, Inc. 1975, New York.
Rostami-Hodjegan Amin and Tucker Geoff ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug-drug interactions. Drug Discovery
Today, 2004, 1, 441–448. The International Transporter Consortium, Membrane transporters in drug development. Nature Review Drug Discovery, 9, 215–236.
Rowland Malcolm and Tozer N. Thomas Clinical Pharmacokinetics Concepts and Applications, 3rd edition. 1995, Lippincott Williams & Wilkins.
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and disease conditions on a drug’s PK. The design strat-
egies are very diverse: single arm or multiple arms, cross-
over or fixed order design, with or without randomization,
with or without stratification, pre-screening or no-pre-screening based on genetic information, prospective or
retrospective studies, and case reports or cohort studies.
The sample size includes the number of subjects, and the
number of plasma or urine samples per subject. The time
points include sampling time points and dosing time
Table 3 In vitro experiment conditions
Experimental
Conditions:
Drugs Substrate, metabolite, and inhibitor/inducer FDA Drug Interaction Guidance,
2006
Metabolism Enzymes Buffer Salt composition
EDTA concentration
MgCl2 concentration Cytochrome b5 concentration














Transporters Bi-Directional CHO; Caco-2 cells; HEK-293; Hepa-RG; LLC; LLC-PK1
MDR1 cells; MDCK; MDCK-MDR1 cells; Suspension
HepatocyteTransport
Uptake/efflux tumor cells, cDNA transfected cells, oocytes injected with
cRNA of transporters
ATPase membrane vesicles from various tissues or cells
expressing P-gp, Reconstituted P-gp




HPLC/UV, LC/MS/MS, LC/MS, radiographic
Sample size
Data Analysis log-linear regression, plotting; and nonlinear regression
Note. http://www.abclabs.com/Portals/0/FDAGuidance_DraftDrugInteractionStudies2006.pdf.
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The drug quantification methods include HPLC/UV, LC/
MS/MS, LC/MS, and radiographic.
CYP450 family enzymes predominantly exist in the gut
wall and liver. Transporters are tissue specific. Table 5 pre-
sents the tissue specific transports and their functions.
Probe drug is another important concept in the pharmacol-
ogy research. An enzyme’s probe substrate means that this
substrate is primarily metabolized or transported by this
enzyme. In order to experimentally prove whether a new
drug inhibits or induces an enzyme, its probe substrate is
always utilized to demonstrate this enzyme’s activity before
and after inhibition or induction. An enzyme’s probe inhibi-
tor or inducer means that it inhibits or induces this enzyme
primarily. Similarly, an enzyme’s probe inhibitor needs to
be utilized if we investigate whether a drug is metabolized
by this enzyme. Table 6 presents all the probe inhibitors,
inducers, and substrates of CYP enzymes. Table 7 presents
all the probe inhibitors, inducers, and substrates of
the transporters. All these information were collected from
industry standard (http://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/ucm064982.
htm), reviewed in the top pharmacology journal [9].Metabolism The cytochrome P450 superfamily (officially
abbreviated as CYP) is a large and diverse group of
enzymes that catalyze the oxidation of organic substances.
The substrates of CYP enzymes include metabolic inter-
mediates such as lipids and steroidal hormones, as well as
xenobiotic substances such as drugs and other toxic che-
micals. CYPs are the major enzymes involved in drug me-
tabolism and bioactivation, accounting for about 75% of
the total number of different metabolic reactions [10]. CYP
enzyme names and genetic variants were mapped from the
Human Cytochrome P450 (CYP) Allele Nomenclature
Database (http://www.cypalleles.ki.se/). This site contains
the CYP450 genetic mutation effect on the protein se-
quence and enzyme activity with associated references.
Transport Proteins are proteins which serves the function
of moving other materials within an organism. Transport
proteins are vital to the growth and life of all living things.
Transport proteins involved in the movement of ions, small
molecules, or macromolecules, such as another protein,
across a biological membrane. They are integral membrane
proteins; that is they exist within and span the membrane
across which they transport substances. Their names and
genetic variants were mapped from the Transporter
Table 4 In vivo PK studies
Category Name Description Unit reference
PK parameters AUCinf Area under the drug concentration time curve. mg h L
-1 RT p37
AUCSS Area under the drug concentration time curve within a dosing curve at steady state. mg h L
-1 RT pxi
AUCt Area under the drug concentration time curve from time 0 to t. mg h L
-1 RT p37
AUMC Area under the first moment of concentration versus time curve. mg2 h L-2 RT p486
AUCR AUC ratio (drug interaction parameter). Unit free
CL Total clearance is defined as the proportionality factor relating rate of drug elimination
to the plasma drug concentration.
ml h-1 RT p23
CLb Blood clearance is defined as the proportionality factor relating rate of drug
elimination to the blood drug concentration.
ml h-1 RT p160
CLu Unbound clearance is defined as the proportionality factor relating rate of drug
elimination to the unbounded plasma drug concentration.
ml h-1 RT p163
CLH Hepatic portion of the total clearance. ml h
-1 RT p161
CLR Renal portion of the total clearance. ml h
-1 RT p161
CLpo Total clearance of drug following an oral dose. ml h
-1
CLIV Total clearance of drug following an IV dose. ml h
-1
CLint Intrinsic metabolic clearance is defined as ratio of maximum metabolism rate, Vmax,
and the Michaelis-Menten constant, Km.
ml h-1 RT p165
CL12 Inter-compartment distribution between the central compartment and the peripheral
compartment.
ml h-1
CL ratio Ratio of the clearance (drug interaction parameter). Unit free
Cmax Highest drug concentration observed in plasma following administration of an
extravascular dose.
mg L-1 RT pxii
Cmax ratio The ratio of Cmax (drug interaction parameter). Unit free
Css Concentration of drug in plasma at steady state during a constant rate intravenous
infusion.
mg L-1 RT pxii
Css ratio The ratio of Css (drug interaction parameter). Unit free
E Extraction ratio is defined as the ratio between blood clearance, CLb, and the blood
flow.
Unit free RT p159
EH Hepatic extraction ratio. Unit free RT p161
F Bioavailability is defined as the proportion of the drug reaches the systemic blood. Unit free RT p42
FG Gut-wall bioavailability. Unit free
FH Hepatic bioavailability. Unit free RT p167
FR Renal bioavailability. Unit free RT p170
fe Fraction of drug systemically available that is excreted unchanged in urine. Unit free RT pxiii
fm Fraction of drug systemically available that is converted to a metabolite. Unit free RT pxiii
fu Ratio of unbound and total drug concentrations in plasma. Unit free RT pxiii
k Elimination rate constant. h-1 RT pxiii
K12, k21 Distribution rate constants between central compartment and peripheral
compartment.
h-1
ka Absorption rate constant. h-1 RT pxiii
ke Urinary excretion rate constant. h-1 RT pxiii
km Rate constant for the elimination of a metabolite. h-1 RT pxiii
Km Michaelis-Menten constant. mg L-1 RT pxiii
MRT Mean time a molecular resides in body. h RT pxiv
Q Blood flow. L h-1 RT pxiv
QH Hepatic blood flow. L h
-1 RT pxiv
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Table 4 In vivo PK studies (Continued)
tmax Time at which the highest drug concentration occurs following administration of an
extravascular dose.
h RT pxiv
t1/2 Half-life of the drug disposition. h RT pxiv
t1/2 ratio Half-life ratio (drug interaction parameter). Unit free
t1/2,α Half-life of the fast phase drug disposition. h
t1/2,β Half-life of the slow phase drug disposition. h
V Volume of distribution based on drug concentration in plasma. L RT pxiv
Vb Volume of distribution based on drug concentration in blood. L RT pxiv
V1 Volume of distribution of the central compartment. L RT pxiv
V2 Volume of distribution of the peripheral compartment. L
Vss Volume of distribution under the steady state concentration. L RT pxiv
Vmax Maximum rate of metabolism by an enzymatically mediated reaction. mg h-1 RT pxiv





Use drug concentration measurements directly to estimate PK parameters, such as AUC, CL, Cmax,





It assumes the whole body is a homogeneous compartment, and the distribution of the drug from
the blood to tissue is very fast. It assumes either a first order or a zero order absorption rate and a






It assumes the whole body can be divided into two compartments: central compartment (i.e.
systemic compartment) and peripheral compartment (i.e. tissue compartment). It assumes either a
first order or a zero order absorption rate and a first order eliminate and distribution rates. Its PK
parameters include (ka, V1, V2, CL, CL12, F).
GP p84
Study Designs Hypothesis Bioequivalence, drug interaction, pharmacogenetics, and disease conditions.
Design Single arm or multiple arms; cross-over or fixed order design; with or without randomization; with
or without stratification; prescreening or no-prescreening; prospective or retrospective studies; and
case reports or cohort studies.
Sample size The number of subjects, and the number of plasma or urine samples per subject.
Time points Sampling time points and dosing time points.
Sample types Blood, plasma, and urine.
Dose Subject specific doses.
Quantification
methods
HPLC/UV, LC/MS/MS, LC/MS, radiographic
Rowland Malcolm and Tozer N. Thomas Clinical Pharmacokinetics Concepts and Applications, 3rd edition. 1995, Lippincott Williams & Wilkins.
Gibaldi Milo and Perrier Donald. Pharmacokinetics, 2nd edition. 1982, Dekker.
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we also added the probe substrates and probe inhibitors to
each one of the metabolism and transportation enzymes
(see prescribed description).
Drug names was created using the drug names from
DrugBank 3.0 [11]. DrugBank consists of 6,829 drugs
which can be grouped into different categories of FDA-
approved, FDA approved biotech, nutraceuticals, and ex-
perimental drugs. The drug names are mapped to generic
names, brand names, and synonyms.
Subject included the existing ontologies for human dis-
ease ontology (DOID), suggested Ontology for Pharmaco-
genomics (SOPHARM),, and mammalian phenotype (MP)
from http://bioportal.bioontology.org (see Table 1)The PK
ontology was implemented with Protégé [12] and uploaded
to the BioPortal ontology platform.PK corpus
A PK abstract corpus was constructed to cover four pri-
mary classes of PK studies: clinical PK studies (n = 56); clin-
ical pharmacogenetic studies (n = 57); in vivo DDI studies
(n = 218); and in vitro drug interaction studies (n = 210).
The PK corpus construction process is a manual process.
The abstracts of clinical PK studies were selected from our
previous work, in which the most popular CYP3A sub-
strate, midazolam was investigated [4]. The clinical phar-
macogenetic abstracts were selected based on the most
polymorphic CYP enzyme, CYP2D6. We think these two
selection strategies represent very well all the in vivo PK
and PG studies. In searching for the drug interaction stud-
ies, the abstracts were randomly selected from a PubMed
query, which used probe substrates/inhibitors/inducers for
metabolism enzymes reported in the Table 6.
Table 5 Tissue specific transporters
Gene Aliases Tissue type Function
ABCB1 P-gp, MDR1 Intestinal enterocyte, kidney proximal tubule, hepatocyte (canalicular), brain endothelia Efflux
ABCG2 BCRP Intestinal enterocyte, hepatocyte (canalicular), kidney proximal tubule, brain endothelia, placenta, stem





SLCO1B3 OATP1B3, OATP-8 Hepatocyte (sinusoidal) Uptake
SLC22A2 OCT2 Kidney proximal tubule Uptake
SLC22A6 OAT1 Kidney proximal tubule, placenta Uptake
SLC22A8 OAT3 Kidney proximal tubule, choroid plexus, brain endothelia Uptake
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their annotation is a manual process (Figure 1). The an-
notation was firstly carried out by three master level
annotators (Shreyas Karnik, Abhinita Subhadarshini, and
Xu Han), and one Ph.D. annotator (Lang Li). They have
different training backgrounds: computational science,
biological science, and pharmacology. Any differentially
annotated terms were further checked by Sara K. Quinney
and David A. Flockhart, one Pharm D. and one M.D.
scientists with extensive pharmacology training back-
ground. Among the disagreed annotations between
these two annotators, a group review was conducted
(Drs Quinney, Flockhart, and Li) to reach the final
agreed annotations. In addition a random subset of 20%
of the abstracts that had consistent annotations among
four annotators (3 masters and one Ph.D.), were double
checked by two Ph.D. level scientists.
A structured annotation scheme was implemented to
annotate three layers of pharmacokinetics information:
key terms, DDI sentences, and DDI pairs (Figure 2). DDI
sentence annotation scheme depends on the key terms;
and DDI annotations depend on the key terms and DDI
sentences. Their annotation schemes are described as
following.
Key terms include drug names, enzyme names, PK
parameters, numbers, mechanisms, and change. The
boundaries of these terms among different annotators
were judged by the following standard.
 Drug names were defined mainly on DrugBank 3.0
[11]. In addition, drug metabolites were also tagged,
because they are important in in vitro studies. The
metabolites were judged by either prefix or suffix:
oxi, hydroxyl, methyl, acetyl, N-dealkyl, N-demethyl,
nor, dihydroxy, O-dealkyl, and sulfo. These prefixes
and suffixes are due to the reactions due to phase I
metabolism (oxidation, reduction, hydrolysis), and
phase II metabolism (methylation, sulphation,
acetylation, glucuronidation) [13].
 Enzyme names covered all the CYP450 enzymes.
Their names are defined in the human cytochromeP450 allele nomenclature database, http://www.
cypalleles.ki.se/. The variations of the enzyme or
gene names were considered. Its regular expression
is (?:cyp|CYP|P450|CYP450)?[0–9][a-zA-Z][0–9]
(?:\*[0–9])?$.
 PK parameters were annotated based on the defined
in vitro and in vivo PK parameter ontology in
Table 2 and 4. In addition, some PK parameters have
different names, CL = clearance, t1/2 = half-life,
AUC = area under the concentration curve, and
AUCR = area under the concentration curve ratio.
 Numbers such as dose, sample size, the values of PK
parameters, and p-values were all annotated. If
presented, their units were also covered in the
annotations.
 Mechanisms denote the drug metabolism and
interaction mechanisms. They were annotated by







 Change describes the change of PK parameters. The
following words were annotated in the corpus to
denote the change: strong(ly)?, moderate(ly)?, high
(est)?(er)?, slight(ly)?, strong(ly)?, moderate(ly)?,
slight(ly)?, significant(ly)?, obvious(ly)?, marked(ly)?,
great(ly)?, pronounced(ly)?, modest(ly)?, probably,
may, might, minor, little, negligible, doesn’t interact,
affect((s|ed)?|ing|ion(s)?)?$, reduc(e(s|d)?|ing|tion
(s)?)$, and increas(e(s|d)?|ing)$.
The middle level annotation focused on the drug inter-
action sentences. Because two interaction drugs were
not necessary all presented in the sentence, sentences
were categorized into two classes:
 Clear DDI Sentence (CDDIS): two drug names (or
drug-enzyme pair in the in vitro study) are in the




CYP1A2 Ciprofloxacin, enoxacin, fluvoxamine,
Methoxsalen, mexiletine, oral contraceptives,
phenylpropanolamine, thiabendazole,
vemurafenib, zileuton, acyclovir, allopurinol,




Montelukast, phenytoin, smokers versus non-
smokers, moricizine, omeprazole,
phenobarbital
Alosetron, caffeine, duloxetine, melatonin,
ramelteon, tacrine, tizanidine, theophylline,
tizanidine
CYP2B6 Clopidogrel, ticlopidine prasugrel Efavirenz, rifampin, nevirapine Bupropion, efavirenz
CYP2C8 Gemfibrozil, fluvoxamine, ketoconazole,
trimethoprim
Rifampin Repaglinide, Paclitaxel






bosentan, phenobarbital, St. John’s wort
Celecoxib, Warfarin, phenytoin
CYP2C19 Fluconazole, fluvoxamine, ticlopidine,
esomeprazole, fluoxetine, moclobemide,
omeprazole, voriconazole, allicin (garlic
derivative), armodafinil, carbamazepine,
cimetidine, etravirine, human growth
hormone (rhGH), felbamate, ketoconazole,
oral contraceptives
Rifampin, artemisinin Clobazam, lansoprazole, omeprazole,
Smephenytoin, S-mephenytoin
CYP3A Boceprevir, clarithromycin, conivaptan,
grapefruit juice, indinavir, itraconazole,
Avasimibe, carbamazepine, phenytoin,
rifampin, St. John’s wort, bosentan, efavirenz,




Alfentanil, aprepitant, budesonide, buspirone,
conivaptan, darifenacin, darunavir, dasatinib,
dronedarone, eletriptan, eplerenone,
everolimus, felodipine, indinavir, fluticasone,
lopinavir, lovastatin, lurasidone, maraviroc,
midazolam, nisoldipine, quetiapine,
saquinavir, sildenafil, simvastatin, sirolimus,
tolvaptan, tipranavir, triazolam, ticagrelor,
vardenafil, Alfentanil, astemizole, cisapride,
cyclosporine, dihydroergotamine,








fluconazole, fosamprenavir, grapefruit juice,
imatinib, verapamil, alprazolam, amiodarone,
amlodipine, atorvastatin, bicalutamide,
cilostazol, cimetidine, cyclosporine,
fluoxetine, fluvoxamine, ginkgo, goldenseal,















propafenone, ranitidine, ritonavir, sertraline,
telithromycin, verapamil, vemurafenib
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either interaction, or non-interaction, or ambiguous
statement (i.e. such as possible or might and etc.).
 Vague DDI Sentence (VDDIS): One drug or enzyme
name is missed in the DDI sentence, but it can be
inferred from the context. Clear interaction
statement also is required.Once DDI sentences were labeled, the DDI pairs in
the sentences were further annotated. Because the fun-
damental difference between in vivo DDI studies and
in vitro DDI studies, their DDI relationships were
defined differently. In in vivo studies, three types of DDI
relationships were defined (Table 8): DDI, ambiguous
DDI (ADDI), and non-DDI (NDDI). Four conditions are
Table 7 In vivo probe inhibitors/inducers/substrates of selected transporters
Transporter Inhibitor Inducer Substrate
P-gp Amiodarone, azithromycin, captopril, carvedilol,
clarithromycin, conivaptan, cyclosporine,
diltiazem, dronedarone, erythromycin, felodipine,
itraconazole, ketoconazole, lopinavir and






Aliskiren, ambrisentan, colchicine, dabigatran
etexilate, digoxin, everolimus, fexofenadine, imatinib,
lapatinib, maraviroc, nilotinib, posaconazole,
ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol,
tolvaptan, topotecan
BCRP Cyclosporine, elacridar (GF120918), eltrombopag,
gefitinib
NA Methotrexate, mitoxantrone, imatinib, irrinotecan,
lapatinib, rosuvastatin, sulfasalazine, topotecan
OATP1B1 Atazanavir, cyclosporine, eltrombopag,
gemfibrozil, lopinavir, rifampin, ritonavir,
saquinavir, tipranavir
NA Atrasentan, atorvastatin, bosentan, ezetimibe,
fluvastatin, glyburide, SN-38 (active metabolite of
irinotecan), rosuvastatin, simvastatin acid,
pitavastatin, pravastatin, repaglinide, rifampin,
valsartan, olmesartan
OATP1B3 Atazanavir, cyclosporine, lopinavir, rifampin,
ritonavir, saquinavir
NA Atorvastatin, rosuvastatin, pitavastatin, telmisartan,
valsartan, olmesartan
OCT2 Cimetidine, quinidine NA Amantadine, amiloride, cimetidine, dopamine,
famotidine, memantine, metformin, pindolol,
procainamide, ranitidine, varenicline, oxaliplatin
OAT1 Probenecid NA Adefovir, captopril, furosemide, lamivudine,
methotrexate, oseltamivir, tenofovir, zalcitabine,
zidovudine
OAT3 Probenecid cimetidine, diclofenac NA Acyclovir, bumetanide, ciprofloxacin, famotidine,
furosemide, methotrexate, zidovudine, oseltamivir
acid, (the active metabolite of oseltamivir), penicillin
G, pravastatin, rosuvastatin, sitagliptin
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http://www.biomedcentral.com/1471-2105/14/35specified to determine these DDI relationships. Condition
1 (C1) requires that at least one drug or enzyme name has
to be contained in the sentence; condition 2 (C2) requires
the other interaction drug or enzyme name can be found
from the context if it is not from the same sentence;Figure 1 PK corpus annotation flow chart.condition 3 (C3) specifies numeric rules to defined the DDI
relationships based on the PK parameter changes; and con-
dition 4 (C4) specifies the language expression patterns for
DDI relationships. Using the rules summarized in Table 8,
DDI, ADDI, and NDDI can be defined by C1 ^ C2 ^ (C3 ^
Figure 2 A three level hierarchical PK and DDI annotation scheme.
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http://www.biomedcentral.com/1471-2105/14/35C4). The priority rank of in vivo PK parameters is AUC >
CL > t1/2 > Cmax. In in vitro studies, six types of DDI rela-
tionships were defined (Table 8). DDI, ADDI, NDDI were
similar to in vivo DDIs, but three more drug-enzyme rela-





DDI Yes Yes The PK parameter with the highest priority* m
<0.05 and FC > 1.50 or FC < 0.67
Ambiguous DDI
(ADDI)
The PK parameter with the highest priority* in
p-value <0.05
but 0.67 < FC < 1.50; or FC >1.50 or FC <0.67,
Non-DDI (NDDI) The PK parameter with the highest priority*are
p-value > 0.05 and 0.67 < FC < 1.50
IN VITRO STUDY








Non-DDI (NDDI) (Ki > 100 microM or EC50 > 100 microM, and
Non-DEI (NDEI)
Note:
C1: At least one drug or enzyme name has to be contained in the sentence.
C2: Need to label the drug name if it is not from the same sentence.
C3: PK-parameter and value dependent.
C4: Significance statement.
*Priority issue: When C3 and C4 occur and conflict, C3 dominates the sentence.**Fo
PK parameters: Ki>IC50.(ADEI), and non-DDI (NDEI). C1, C2, and C4 remained
the same for in vitro DDIs. The main difference is in C3, in
which either Ki or IC50 (inhibition) or EC50 (induction)
were used to defined DDI relationship quantitatively. The
priority rank of in vitro PK parameters is Ki > IC50. Table 9C4**
ust satisfy p-value Significant, obviously, markedly, greatly,
pronouncedly and etc.
the conditions of
but p-value > 0.05.
Modestly, moderately, probably, may, might, and
etc.
in the condition of Minor significance, slightly, little or negligible
effect, doesn’t interact etc.
lue <0.05) Significant, obviously, markedly, greatly,
pronouncedly and etc.
d p-value <0.05 or Modestly, moderately, probably, may, might, and
etc.
p-value >0.05) Minor significance, slightly, little or negligible
effect, doesn’t interact etc.
r the priority of PK parameters: AUC > CL > t1/2 > Cmax;; the priority of in vitro
Table 9 Examples of DDI definitions
PMID DDI sentence Relationship and commend
20012601 The pharmacokinetic parameters of verapamil were significantly altered
by the co-administration of lovastatin compared to the control.
Because of the words, “significantly”, (Verapamil, lovastatin) is a
DDI.
20209646 The clearance of mitoxantrone and etoposide was decreased by 64% and
60%, respectively, when combined with valspodar.
Because of the fold changes were less than 0.67, (mitoxantrone,
valspodar.) and (etoposide, valspodar) are DDIs.
20012601 The (AUC (0-infinity)) of norverapamil and the terminal half-life of
verapamil did not significantly changed with lovastatin coadministration.
Because of the words, “not significantly changed”, (verapamil,
ovastatin) is a NDDI.
17304149 Compared with placebo, itraconazole treatment significantly increase the
peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 2.5
versus 9.0 3.3 ng/mL, P≤0.05) and the area under the plasma
concentration-time curve from zero to 48 hours [AUC(0–48)] of
paroxetine by 1.5 fold (137 73 versus 199 91 ng*h/mL, P≤0.01).
AUC has a higher rank than Cmax, and it had a 1.5 fold-change
and less than 0.05 p-value, thus, (itraconazole, paroxetine) is a
DDI.
13129991 The mean (SD) urinary ratio of dextromethorphan to its metabolite was
0.006 (0.010) at baseline and 0.014 (0.025) after St John’s wort
administration (P=.26)
The change in PK parameter is more than 1.5 fold but P-value
is >0.05. Thus, (dextromethorphan, St John’s wort) is an ADDI.
19904008 The obtained results show that perazine at its therapeutic
concentrations is a potent inhibitor of human CYP1A2.
Because of words, “potent inhibitor”, (perazine, CYP1A2) is a
DEI.
19230594 After human hepatocytes were exposed to 10 microM YM758,
microsomal activity and mRNA level for CYP1A2 were not induced while
those for CYP3A4 were slightly induced.
Because of words, “not induced” and “slightly induced”,
(YM758, CYP1A2) and (YM758, CYP1A2) are NDEIs.
19960413 From these results, DPT was characterized to be a competitive inhibitor
of CYP2C9 and CYP3A4, with K(i) values of 3.5 and 10.8 microM in HLM
and 24.9 and 3.5 microM in baculovirus-insect cell-expressed human
CYPs, respectively.
Because K was larger than 10microM, (DPT, CYP2C9) and (DPT,
CYP3A4) are ADEIs.
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mined in the sentences.
Krippendorff ’s alpha [14] was calculated to evaluate
the reliability of annotations from four annotators. The
















CDDI sentences 1191 0.921
VDDI sentences 120
Total sentences 4724






Total Drug Pairs 12399are presented in Table 10. Their Krippendorff ’s alphas
are 0.953, 0.921, and 0.905, respectively. Please note that
the total DDI pairs refer to the total pairs of drugs
within a DDI sentence from all DDI sentences.
The PK corpus was constructed by the following
process. Raw abstracts were downloaded from PubMed
in XML format. Then XML files were converted into
GENIA corpus format following the gpml.dtd from the
GENIA corpus [15]. The sentence detection in this step
is accomplished by using the Perl module Lingua::EN::
Sentence, which was downloaded from The Comprehensive
Perl Archive Network (CPAN, www.cpan.org). GENIA cor-
pus files were then tagged with the prescribed three levels
of PK and DDI annotations. Finally, a cascading style sheet
(CSS) was implemented to differentiate colours for the en-
tities in the corpus. This feature allows the users to visualize
annotated entities. We would like to acknowledge that a
DDI Corpus was recently published as part of a text mining
competition DDIExtraction 2011 (http://labda.inf.uc3m.es/
DDIExtraction2011/dataset.html). Their DDIs were clinical
outcome oriented, not PK oriented. They were extracted
from DrugBank, not from PubMed abstracts. Our PK cor-
pus complements to their corpus very well.
Utility
Example 1: An annotated tamoxifen pharmacogenetics
study
This example shows how to annotate a pharmacogenetics
studies with the PK ontology. We used a published tam-
oxifen PG study [16]. The key information from this
Figure 3 Drug interaction extraction algorithm flow chart.
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the pre-processed information was mapped to the PK
ontology (column 2 in Additional file 1: Table S1). This
PG study investigates the genetics effects (CYP3A4,
CPY3A5, CYP2D6, CYP2C9, CYP2B6) on the tamoxifen
pharmacokinetics outcome (tamoxifen metabolites)
among breast cancer patients. It was a single armTable 11 DDI data description




in vivo DDI training 174 2112 2024 359
in vivo DDI testing 44 545 574 45
in vitro DDI training 168 1894 7122 783
in vitro DDI testing 42 475 1542 146longitudinal study (n = 298), patients took SOLTA-
MOXTM 20mg/day, and the drug steady state concentra-
tion was sampled (1, 4, 8, 12) months after the tamoxifen
treatment. The study population was a mixed Caucasian
and African American. In additional file 1: Table S1, the
trial summary is well organized by the PK ontology.
Example 2 midazolam/ketoconazole drug interaction
study
This was a cross-over three-phase drug interaction study
[17] (n = 24) between midazolam (MDZ) and ketocona-
zole (KTZ). Phase I was MDZ alone (IV 0.05 mg/kg and
PO 4mg); phase II was MDZ plus KTZ (200mg); and
phase III was MDZ plus KTZ (400mg). Genetic variable
include CYP3A4 and CYP3A5. The PK outcome is the
MDZ AUC ratio before and after KTZ inhibition. Its PK
Table 12 DDI extraction performance
Datasets precision recall f-measure
in vivo DDI Training 0.67 0.78 0.72
in vivo DDI Testing 0.67 0.79 0.73
in vitro DDI Training 0.51 0.59 0.55
in vitro DDI Testing 0.47 0.58 0.52
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Table S1 column three.Example 3 in vitro Pharmacokinetics Study
This was an in vitro study [18], which investigated the
drug metabolism activities for 3 enzymes, such as
CYP3A4, CYP3A5, and CYP3A7 in a recombinant sys-
tem. Using 10 CYP3A substrates, they compared the
relative contribution of 3 enzymes among 10 drug’s me-
tabolism. Its PK ontology based annotation is shown in
Additional file 1: Table S2.Table 13 DDI extraction error analysis from testing DDI sets
No. Error categories Error type




2 There is no direct DDI relationship between two drugs,
but the presence of some words, such as dose, increase,
and etc. may lead to a false positive prediction
FP
3 DDI is presented in an indirect way. FN
4 Design issue. Some NDDI are inferred due to some
adjectives (little, minor, negligible)
FP
5 Unknown FP
FNExample 4 A drug interaction text mining example
We implemented the approach described by [19] for the
DDI extraction. Prior to performing DDI extraction, the
testing and validation DDI abstracts in our corpus was
pre-processed and converted into the unified XML for-
mat [19]. The following steps were conducted:
 Drugs were tagged in each of the sentences using
dictionary based on DrugBank. This step revised our
prescribed drug name annotations in the corpus.
One purpose is to reduce the redundant
synonymous drug names. The other purpose is only
keep the parent drugs and remove the drug
metabolites from the tagged drug names from our
initial corpus, because parent drugs and their
metabolites rarely interacts. In addition, enzymes
(i.e. CYPs) were also tagged as drugs, since enzyme-
drug interactions have been extensively studied and
published. The regular expression of enzyme names
in our corpus was used to remove the redundant





6 34 PMID: 12426514. In 3 subjects with measurable
concentrations in the single-dose study, rifampin
significantly decreased the mean maximum plasma
concentration (C(max)) and area under the plasma
concentration-time curve from 0 to 24 h [AUC(0–24)] of
praziquantel by 81% (P <.05) and 85% (P <.01),
respectively, whereas rifampin significantly decreased the
mean C(max) and AUC(0–24) of praziquantel by 74% (P
<.05) and 80%
(P <.01), respectively, in 5 subjects with measurable
concentrations in the multiple-dose study
2 17 PMID: 10608481. Erythromycin and ketoconazole showed
a clear inhibitory effect on the 3-hydroxylation of
lidocaine at 5 microM of lidocaine (IC50 9.9 microM and
13.9 microM, respectively), but did not show a consistent
effect at 800 microM of lidocaine (IC50 >250 microM and
75.0 microM, respectively).
6 14 PMID: 17192504. A significant fraction of patients to be
treated with HMR1766 is expected to be maintained on
warfarin
2 19 PMID: 11994058. In CYP2D6 poor metabolizers, systemic
exposure was greater after chlorpheniramine alone than
in extensive metabolizers, and administration of quinidine
resulted in a slight increase in CLoral.
1 3 PMID: 10223772. In contrast,the effect of ranitidine or
ebrotidine on CYP3A activity in vivo seems to have little
clinical significance.
5 44 PMID: 10383922. CYP1A2, CYP2A6, and CYP2E1 activities
were not significantly inhibited by azelastine and the two
metabolites.
6 26 PMID: 10681383. However, the most unusual result was
the interaction between testosterone and nifedipine.
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PoS tags and dependency tree generation using the
Stanford parser [20].
 C2n drug pairs form the tagged drugs in a sentence
were generated automatically, and they were assigned
with default labels as no-drug interaction. Please note
that if a sentence had only one drug name, this
sentence didn’t have a DDI. This setup limited us
considering only CDDI sentence in our corpus.
 The drug interaction labels were then manually
flipped based on their true drug interaction
annotations from the corpus. Please note that our
corpus had annotated DDIs, ADDIs, NDDIs, DEIs,
ADEIs, and NDEIs. Here only DDIs and DEIs were
labeled as true DDIs. The other ADDIs, NDDIs,
DEIs, and ADEIs were all categorized into the no-
drug interactions.
Then sentences were represented with dependency
graphs using interacting components (drugs) (Figure 3).
The graph representation of the sentence was composed
of two items: i) One dependency graph structure of
the sentence; ii) a sequence of PoS tags (which was
transformed to a linear order “graph” by connecting the
tags with a constant edge weight). We used the Stanford
parser [20] to generate the dependency graphs. Airola
et al. proposed to combine these two graphs to one
weighted, directed graph. This graph was fed into a sup-
port vector machine (SVM) for DDI/non-DDI classifica-
tion. More details about the all paths graph kernel
algorithm can be found in [19]. A graphical representa-
tion of the approach is presented in Figure 3.
DDI extraction was implemented in the in vitro and
in vivo DDI corpus separately. Table 11 presented the
training sample size and testing sample size in both cor-
pus sets. Then Table 12 presents the DDI extraction per-
formance. In extracting in vivo DDI pairs, the precision,
recall, and F-measure in the testing set are 0.67, 0.79,
and 0.73, respectively. In the in vitro DDI extraction
analysis, the precision, recall, and F-measure are 0.47,
0.58, 0.52 respectively in the in vitro testing set. In our
early DDI research published in the DDIExtract 2011
Challenge [21], we used the same algorithm to extract
both in vitro and in vivo DDIs at the same time, the
reported F-measure was 0.66. This number is in the
middle of our current in vivo DDI extraction F-measure
0.73 and in vitro DDI extraction F-measure 0.52.
Error analysis was performed in testing samples. Table 13
summarized the results. Among the known reasons for
the false positives and false negatives, the most frequent
one is that there are multiple drugs in the sentence, or the
sentence is long. The other reasons include that there is
no direct DDI relationship between two drugs, but the
presence of some words, such as dose, increase, and etc.,may lead to a false positive prediction; or DDI is presented
in an indirect way; or some NDDI are inferred due to
some adjectives (little, minor, negligible).
Conclusions and discussions
A comprehensive PK ontology was constructed. It anno-
tates both in vitro PK experiments and in vivo PK studies.
Using our PK ontology, a PK corpus was also developed.
It consists of four classes of PK studies: in vivo PK studies,
in vivo PG studies, in vivo DDI interaction studies, and
in vitro DDI studies. This PK corpus is a highly valuable
resource for text mining drug interactions relationship.
We previously had developed entity recognition algo-
rithm or tools to tag PK parameters and their associated
numerical data [4]. We had shown that for one drug,
midazolam, we have achieved very high accuracy and re-
call rate in tagging PK parameter, clearance (CL), and its
associated numerical values. However, using our newly
developed PK corpus, we cannot regain such a good per-
formance in a more general class of drugs and PK para-
meters. This area will need much further investigation.
We would like to acknowledge that a DDI Corpus
was recently published as part of a text mining compe-
tition DDIExtraction 2011 (http://labda.inf.uc3m.es/DDIEx-
traction2011/dataset.html). Their DDIs were clinical
outcome oriented, not PK oriented. They were extracted
from DrugBank, not from PubMed abstracts. Our PK cor-
pus complements to their corpus very well.
Availability and requirements
PK ontology is available in OWL for download at http://
rweb.compbio.iupui.edu/corpus/ontology/, which can be
accessed by using any OWL editor/viewer, e.g., protégé.
PK corpuses are available in XML at http://rweb.comp-
bio.iupui.edu/corpus/.
Additional file
Additional file 1: Table S1. Clinical PK Studies. Table S2. in vitro PK
studies.
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speech; PK: Pharmacokinetics; PG: Pharmacogenetics.
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